Glenn Pierce, M.D., Ph.D.
Dr. Pierce has served as a member of GBT’s board of directors since February 2016. He has more than 30 years of experience leading research and development at biotechnology and biopharmaceutical firms. Dr. Pierce serves as an independent consultant and entrepreneur-in-residence at Third Rock Ventures, a venture capital firm. He co-founded Ambys Medicines and served as interim chief medical officer from January 2018 to March 2022. He also serves on the World Federation of Hemophilia (WFH) Board and the National Hemophilia Foundation (NHF) (U.S.) Medical and Scientific Advisory Council. Dr. Pierce is also a director of Voyager Therapeutics, and serves as interim chief scientific officer. Previously, he was senior vice president of hematology, cell and gene therapies at Biogen, where he had overall R&D responsibility for hemophilia and hemoglobinopathies. As chief medical officer at Biogen, he led the research and clinical development of extended half-life FVIII and FIX Fc fusions, which culminated in multiple regulatory approvals. Dr. Pierce was also responsible for global medical affairs for Biogen’s portfolio, and he spearheaded the initiation of a 5-year humanitarian aid clotting factor distribution program with WFH and My Life, Our Future, a population-wide genomic biobank initiative with the NHF and other partners. He is the co-author of more than 150 scientific papers and is a named inventor in over 15 patents. He served on the Blood Products Advisory Committee at the U.S. Food and Drug Administration and the Advisory Committee on Blood Safety and Availability at the U.S. Department of Health and Human Services. Dr. Pierce received an M.D. and a Ph.D. in immunology from Case Western Reserve University and did postgraduate training in pathology and hematology research at Washington University.